This article is more than 5 years old. Information may no longer be current.
Visual improvements maintained through week 96 of VIEW studies
LAS VEGAS — The 96-week results of the VIEW 1 and 2 studies indicate that visual gains were maintained in patients receiving aflibercept or ranibizumab for the treatment of neovascular AMD, a speaker said here.
“Visual improvements in the VIEW trial were maintained through year 2,” Allen C. Ho, MD, said.
Allen C. Ho
The studies enrolled 2,457 patients in four arms. Patients received intravitreal injections of either 0.5 mg ranibizumab (Lucentis, Genentech) every 4 weeks, 2 mg aflibercept (Eylea, Regeneron) every 4 weeks, 0.5 mg aflibercept every 4 weeks or 2 mg aflibercept every 8 weeks with three monthly loading doses.
In the second year, which employed an as-needed modified quarterly treatment schedule, the mean number of injections was lowest in the group treated with 2 mg of aflibercept every 8 weeks, Ho told colleagues at the American Society of Retina Specialists meeting.
“For balance, a less-than-monthly Lucentis group was not explored in the first year,” he said.
Kaplan-Meier analysis showed that 2 mg of aflibercept separated and created fluid-free macula faster than ranibizumab, according to Ho. Fewer patients in the 2-mg aflibercept groups required more injections in the second year compared with the 0.5-mg ranibizumab and 0.2-mg aflibercept groups.
“It’s nice to have two safe and efficacious options for patients with neovascular AMD,” Ho said.
-
Disclosure: Ho has served as a consultant for Genentech and Regeneron.